+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen, Line Of Therapy, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen, Line Of Therapy, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen, Line Of Therapy, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084545
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Duvelisib’s integration into relapsed CLL and SLL therapy represents a pivotal development for industry leaders seeking innovative approaches to complex hematologic cancers. As targeted therapies reshape commercial and clinical benchmarks, the market’s trajectory is heavily influenced by competition, regional differences, and evolving regulatory frameworks.

Market Snapshot: Duvelisib in Relapsed CLL/SLL

The global duvelisib market is defined by robust demand in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) populations, where unmet needs persist following multiple treatment lines. Recent regulatory approvals and adoption of mechanism-driven therapeutics are accelerating market expansion. Competitive differentiation, particularly among PI3K inhibitors and next-generation targeted agents, is creating a dynamic landscape for stakeholders. Strategic alliances, patient support innovations, and digital integration further contribute to the evolving market profile.

Scope & Segmentation

This comprehensive market analysis dissects duvelisib’s commercial environment through careful segmentation, regional assessment, and competing technology review. Major focus areas include:

  • Treatment Regimen: Combination therapy, monotherapy
  • Line Of Therapy: Second-line, third-line and above
  • Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy, specialty pharmacy
  • End User: Homecare service, hospital, specialty clinic
  • Patient Age Group: Adult, geriatric
  • Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Competitive Landscape: AbbVie Inc., Johnson & Johnson, AstraZeneca plc, Roche Holding AG, BeiGene, Ltd., Gilead Sciences, Inc., Verastem Oncology, Inc.

Segmentation delivers insight into prescribing behaviors, regional adoption, patient preferences, and logistical models, equipping decision-makers with actionable intelligence.

Key Takeaways for Senior Decision-Makers

  • Duvelisib’s dual PI3K-delta and PI3K-gamma inhibition offers a targeted alternative for patients facing limited options after multiple lines of therapy, supporting its integration in personalized oncology care pathways.
  • Emergence of combination regimens and digital support tools is expanding possibilities for improved adherence, enhanced monitoring, and multi-agent protocols, particularly in heavily pretreated populations.
  • Regional differentiation in market access, reimbursement, and technology deployment drives the need for locally tailored commercial strategies and partnerships with specialized distributors and care providers.
  • Strategic alliances—ranging from academic collaborations to co-development agreements—strengthen portfolio positioning and drive formulary placements in competitive global markets.
  • Real-world evidence and lifecycle management, such as pursuit of earlier-line approvals and dosing innovations, are instrumental for maintaining clinical and commercial relevance amid increasing competition from biosimilars and generics.

The Impact of 2025 US Tariff Adjustments

Imminent tariff changes in the United States are poised to increase the cost base for imported active pharmaceutical ingredients and finished products. These dynamics prompt stakeholders to pursue supply chain localization, reinforce pricing agility, and foster collaborative relationships with domestic and offshore partners. Early alignment with payers and transparent pharmacoeconomic assessments will be critical to preserving market access and value-based contracting as fiscal scrutiny intensifies.

Methodology & Data Sources

Findings are built upon a rigorous research approach that included comprehensive secondary reviews—regulatory filings, clinical data, industry publications—and primary interviews with clinicians, pharmacists, and payers across all key geographies. Mixed-method analysis and cross-validation with real-world datasets ensured robust, up-to-date insights for each market, segment, and stakeholder group.

Why This Report Matters

  • Enables strategic planning by delivering nuanced perspectives on duvelisib’s clinical positioning and commercial potential in diverse markets.
  • Arms decision-makers with segmentation-driven intelligence—critical for identifying growth opportunities, refining investment priorities, and mitigating risk amid shifting regulatory and economic landscapes.

Conclusion

Duvelisib establishes a differentiated therapeutic value in relapsed CLL/SLL, offering stakeholders untapped commercial and clinical opportunities. As regional and regulatory influences grow more complex, data-driven strategy and collaboration are essential to optimize outcomes.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Duvelisib for Relapsed CLL/SLL Market, by Treatment Regimen
8.1. Introduction
8.2. Combination Therapy
8.3. Monotherapy
9. Duvelisib for Relapsed CLL/SLL Market, by Line Of Therapy
9.1. Introduction
9.2. Second-Line
9.3. Third-Line And Above
10. Duvelisib for Relapsed CLL/SLL Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.5. Specialty Pharmacy
11. Duvelisib for Relapsed CLL/SLL Market, by End User
11.1. Introduction
11.2. Homecare Service
11.3. Hospital
11.4. Specialty Clinic
12. Duvelisib for Relapsed CLL/SLL Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
13. Americas Duvelisib for Relapsed CLL/SLL Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Duvelisib for Relapsed CLL/SLL Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Duvelisib for Relapsed CLL/SLL Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Johnson & Johnson
16.3.3. AstraZeneca plc
16.3.4. Roche Holding AG
16.3.5. BeiGene, Ltd.
16.3.6. Gilead Sciences, Inc.
16.3.7. Verastem Oncology, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DUVELISIB FOR RELAPSED CLL/SLL MARKET MULTI-CURRENCY
FIGURE 2. DUVELISIB FOR RELAPSED CLL/SLL MARKET MULTI-LANGUAGE
FIGURE 3. DUVELISIB FOR RELAPSED CLL/SLL MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DUVELISIB FOR RELAPSED CLL/SLL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DUVELISIB FOR RELAPSED CLL/SLL MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DUVELISIB FOR RELAPSED CLL/SLL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY THIRD-LINE AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOMECARE SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 37. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 38. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 42. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 43. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 63. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 64. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 68. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 72. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 73. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 74. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 78. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 79. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 83. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 84. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 88. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 89. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 93. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 97. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 98. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 99. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 103. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 108. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 113. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 114. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 118. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 119. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 122. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 123. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 124. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 127. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 133. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 134. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 138. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 139. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 143. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 144. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 153. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 154. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 157. POLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 158. POLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 159. POLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. POLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. POLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 162. SWITZERLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 163. SWITZERLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 164. SWITZERLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SWITZERLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. CHINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 174. CHINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 175. CHINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. CHINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. CHINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. INDIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 179. INDIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 180. INDIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. INDIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. INDIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 183. JAPAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 184. JAPAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 185. JAPAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. JAPAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. JAPAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. THAILAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 204. THAILAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 205. THAILAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. THAILAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. THAILAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. VIETNAM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. TAIWAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 233. DUVELISIB FOR RELAPSED CLL/SLL MARKET SHARE, BY KEY PLAYER, 2024
TABLE 234. DUVELISIB FOR RELAPSED CLL/SLL MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Duvelisib for Relapsed CLL/SLL market report include:
  • AbbVie Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Roche Holding AG
  • BeiGene, Ltd.
  • Gilead Sciences, Inc.
  • Verastem Oncology, Inc.

Related Topics

Related Reports

Pharmaceuticals - Enterprise ICT - Product Image

Pharmaceuticals - Enterprise ICT

  • Report
  • 54 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
TIL Therapies Market Report and Forecast 2025-2034 - Product Image

TIL Therapies Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Columvi Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Columvi Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.